Stocks · News reference
TG Therapeutics Ranked Number 5 on 2026 Deloitte Technology Fast 500
TG Therapeutics, Inc. has been recognized as the fifth fastest-growing company in North America on the 2026 Deloitte Technology Fast 500 list.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TG Therapeutics Named a Top 5 Small Employer in BioSpace's 2027 Best Places to Work List
TG Therapeutics has been recognized as one of the top five small employers in the biopharmaceutical industry in BioSpace's 2027 Best Places to Work list.
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
TG Therapeutics Q3 2026 Earnings Call Transcript
TG Therapeutics (NASDAQ:TGTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
TG Therapeutics announced its financial results for the third quarter of 2026, reporting revenue of $259.9 million and raising its full-year revenue guidance.
TG Therapeutics Raises FY2026 Sales Guidance from $950.000M to $1.000B vs $960.306M Est